Niebling Janina, Bethge Wolfgang, Lengerke Claudia
Dtsch Med Wochenschr. 2022 Nov;147(23):1552-1564. doi: 10.1055/a-1932-8145. Epub 2022 Nov 16.
Chimeric antigen receptor T cells (CAR T cells) are genetically modified autologous or allogeneic T lymphocytes that target specific antigens and can be used to combat tumor cells. The approval studies show a high response and remission rate in heavily pretreated patients with aggressive B-cell lymphoma, acute lymphoblastic leukemia or multiple myeloma. The article presents the indications for approval, the clinical implementation and the management of side effects of CAR cell therapy.
嵌合抗原受体T细胞（CAR-T细胞）是经过基因改造的自体或异体T淋巴细胞，可靶向特定抗原，用于对抗肿瘤细胞。批准研究表明，在接受过大量预处理的侵袭性B细胞淋巴瘤、急性淋巴细胞白血病或多发性骨髓瘤患者中，CAR-T细胞疗法具有较高的应答率和缓解率。本文介绍了CAR-T细胞疗法的获批适应症、临床应用及副作用管理。
